-
Building Health Equity and Multidirectional Trust in Cancer Care_Breast & Colorectal Cancer_Lisa Newman, MD, MPH, FACS, FASCO, FSSO_Laura Musselwhite, MD, MPH
50:13
-
IUCLS 2023 Friday General Session_Sonali Smith, MD, FASCO_Andrew Evens, DO, MBA, MSc_Timothy Fenske, MD, MS
11:03
-
IUCLS 2023 Friday Interprofessional Session_Sonali Smith, MD, FASCO_Andrew Evens, DO, MBA, MSc_Timothy Fenske, MD, MS
10:30
-
IUCLS 2023 Saturday Afternoon General Session_Sonali Smith, MD, FASCO_Andrew Evens, DO, MBA, MSc_Timothy Fenske, MD, MS
3:34
-
Module 1: Ibrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs_MD_Anthony Mato, MD, MSCE
9:28
-
Module 1_Introduction and Rationale for Targeting BCMA on MM Cells
10:45
-
Module 2: Acalabrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MSCE
8:16
-
Module 2_BCMA-Targeted CAR T-cells
24:20
-
Module 3: Zanubrutinib for Hematologic Malignancies_Matthew Davids, MD, MMSc_Catherine Coombs, Anthony Mato, MD, MSCE
7:59
-
Module 3_BCMA-Targeted Antibody-Drug Conjugates (ADCs)
9:40
-
Module 4: Emerging BTK Inhibitors_Matthew Davids, MD, MMSc_Catherine Coombs, MD_Anthony Mato, MD, MSCE
12:02
- Next Page
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company